Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Denudin is a herbal dietary supplement syrup developed by Synthaverse (formerly known as Biomed-Lublin). It is formulated with dry extracts of ginger rhizome (*Zingiber officinale*) and chamomile flower (*Matricaria chamomilla*). The product is primarily indicated for the relief of nausea, including motion sickness and morning sickness during early pregnancy. Ginger is traditionally utilized for its anti-emetic properties, which are attributed to the antagonism of 5-HT3 and muscarinic receptors in the gastrointestinal tract. Chamomile contributes spasmolytic and soothing effects to alleviate general digestive discomfort. Denudin is intended for use in adults and children from 6 years of age.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Denudin.